Cette liste est basée sur les listes de surveillance des personnes sur Stock Events qui suivent NVV1.F. Il ne s'agit pas d'une recommandation d'investissement.
Sur la base de 6 notations au cours des 6 derniers mois. Il ne s'agit pas d'une recommandation d'investissement.
Acheter
50%
Détenir
33%
Vendre
17%
À propos de nous
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.